FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035134820> ?p ?o ?g. }

• W3035134820 endingPage "300" @default.
• W3035134820 startingPage "300.1" @default.
• W3035134820 abstract "Background: The use of biological therapies during pregnancy has been contraindicated since the beginning of the use of these drugs. In recent years several studies have demonstrated the minimal-to-no transfer of certolizumab pegol (CZP) to the placenta and breast milk, which has allowed its approval for use in pregnancy and breastfeeding if clinically necessary. However, there are no studies evaluating the use of CZP during this period in real life or the characteristics of this subgroup of patients. Objectives: To describe the profile of women of childbearing age diagnosed with chronic inflammatory rheumatic disease (CIRD): Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and axial Spondyloarthritis (axSpA), who initiate CZP by gestational desire using the GESTAMAD registry (multicenter study of women with chronic inflammatory rheumatic disease of childbearing age who are initiated on CPZ by gestational desire from the Madrid community). Methods: Prospective multicenter study that aims to know the characteristics of women of childbearing age diagnosed with CIRD and gestational desire to which CZP is initiated for this reason. The comorbidities of the patients such as hypertension, diabetes and cardiovascular disease were collected. Disease activity was measured by DAS28 using CRP in RA and PsA and BASDAI in axSpA. The present study presents preliminary data from the initial cohort and will be followed prospectively for 24 months to assess the efficacy and safety of the drug during pre-conception, pregnancy and lactation. Results: A total of 45 patients have been recruited in 6 Madrid hospitals from June to December 2019. Patients had a mean age of 35.9, (36.6 in RA, 35.2 in PA and 35.1 in SPA). Fifty-one percent had RA, 20.0 percent had PA and 28.8 percent had SPA. The mean disease duration for RA, PA and SPA was 9.5, 7.3 and 6.9 years, respectively. 48.9% of women were nulliparous. The abortion rate of patients diagnosed with spondyloarthropathy was upper of 25%. 33.3% of the patients had been treated with previous biologicals, with gestational desire/pregnancy being the reason for the change. 75.5% of the patients had been treated with synthetic disease modifying antirheumatic drugs (DMARD) previously. With regard to disease activity, the mean DAS 28 at the start of treatment was 4.5 in RA and 3.8 in PA and BASDAI 7.0 in axSPA. In RA the highest values of CRP and ESR were found prior to initiation with CZP, but this difference was not statistically significant (p=0.644 and 0.605, respectively). 22.2% of patients had previous comorbidities. Conclusion: The mean age of patients with gestational desire in CIRD is high. Women diagnosed with PsA and axSpA have a high rate of previous abortions, upper than 25%. The duration of the disease is equally long at the time of manifesting gestational desire. The use of treatments such as CZP, compatible with pregnancy and lactation would allow a better control of inflammatory joint disease in this period of life, encouraging patients not to postpone their gestational desire. Disclosure of Interests: None declared" @default.
• W3035134820 created "2020-06-19" @default.
• W3035134820 creator A5002959511 @default.
• W3035134820 creator A5019596498 @default.
• W3035134820 creator A5034919047 @default.
• W3035134820 creator A5038348871 @default.
• W3035134820 creator A5039737999 @default.
• W3035134820 creator A5046612816 @default.
• W3035134820 creator A5053851267 @default.
• W3035134820 creator A5066428181 @default.
• W3035134820 creator A5070760495 @default.
• W3035134820 creator A5072333244 @default.
• W3035134820 date "2020-06-01" @default.
• W3035134820 modified "2023-09-27" @default.
• W3035134820 title "THU0168 GESTATIONAL DESIRE AND CERTOLIZUMAB PEGOL IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASE. PRELIMINARY RESULTS OF THE GESTAMAD COHORT" @default.
• W3035134820 doi "https://doi.org/10.1136/annrheumdis-2020-eular.4930" @default.
• W3035134820 hasPublicationYear "2020" @default.
• W3035134820 type Work @default.
• W3035134820 sameAs 3035134820 @default.
• W3035134820 citedByCount "0" @default.
• W3035134820 crossrefType "journal-article" @default.
• W3035134820 hasAuthorship W3035134820A5002959511 @default.
• W3035134820 hasAuthorship W3035134820A5019596498 @default.
• W3035134820 hasAuthorship W3035134820A5034919047 @default.
• W3035134820 hasAuthorship W3035134820A5038348871 @default.
• W3035134820 hasAuthorship W3035134820A5039737999 @default.
• W3035134820 hasAuthorship W3035134820A5046612816 @default.
• W3035134820 hasAuthorship W3035134820A5053851267 @default.
• W3035134820 hasAuthorship W3035134820A5066428181 @default.
• W3035134820 hasAuthorship W3035134820A5070760495 @default.
• W3035134820 hasAuthorship W3035134820A5072333244 @default.
• W3035134820 hasConcept C126322002 @default.
• W3035134820 hasConcept C131872663 @default.
• W3035134820 hasConcept C187212893 @default.
• W3035134820 hasConcept C188816634 @default.
• W3035134820 hasConcept C2776215756 @default.
• W3035134820 hasConcept C2776260265 @default.
• W3035134820 hasConcept C2777077863 @default.
• W3035134820 hasConcept C2777138892 @default.
• W3035134820 hasConcept C2779134260 @default.
• W3035134820 hasConcept C2779234561 @default.
• W3035134820 hasConcept C2779434492 @default.
• W3035134820 hasConcept C46973012 @default.
• W3035134820 hasConcept C54355233 @default.
• W3035134820 hasConcept C71924100 @default.
• W3035134820 hasConcept C72563966 @default.
• W3035134820 hasConcept C86803240 @default.
• W3035134820 hasConceptScore W3035134820C126322002 @default.
• W3035134820 hasConceptScore W3035134820C131872663 @default.
• W3035134820 hasConceptScore W3035134820C187212893 @default.
• W3035134820 hasConceptScore W3035134820C188816634 @default.
• W3035134820 hasConceptScore W3035134820C2776215756 @default.
• W3035134820 hasConceptScore W3035134820C2776260265 @default.
• W3035134820 hasConceptScore W3035134820C2777077863 @default.
• W3035134820 hasConceptScore W3035134820C2777138892 @default.
• W3035134820 hasConceptScore W3035134820C2779134260 @default.
• W3035134820 hasConceptScore W3035134820C2779234561 @default.
• W3035134820 hasConceptScore W3035134820C2779434492 @default.
• W3035134820 hasConceptScore W3035134820C46973012 @default.
• W3035134820 hasConceptScore W3035134820C54355233 @default.
• W3035134820 hasConceptScore W3035134820C71924100 @default.
• W3035134820 hasConceptScore W3035134820C72563966 @default.
• W3035134820 hasConceptScore W3035134820C86803240 @default.
• W3035134820 hasIssue "Suppl 1" @default.
• W3035134820 hasLocation W30351348201 @default.
• W3035134820 hasOpenAccess W3035134820 @default.
• W3035134820 hasPrimaryLocation W30351348201 @default.
• W3035134820 hasRelatedWork W1968116260 @default.
• W3035134820 hasRelatedWork W2031615899 @default.
• W3035134820 hasRelatedWork W2056457467 @default.
• W3035134820 hasRelatedWork W2186200056 @default.
• W3035134820 hasRelatedWork W2353304521 @default.
• W3035134820 hasRelatedWork W2409168192 @default.
• W3035134820 hasRelatedWork W2614365095 @default.
• W3035134820 hasRelatedWork W3214946179 @default.
• W3035134820 hasRelatedWork W4210993797 @default.
• W3035134820 hasRelatedWork W4236587835 @default.
• W3035134820 hasVolume "79" @default.
• W3035134820 isParatext "false" @default.
• W3035134820 isRetracted "false" @default.
• W3035134820 magId "3035134820" @default.
• W3035134820 workType "article" @default.